Avacta Share Discussion Threads

[lordlucan1] 16/8/2021 09:05

Sub £1 end of week

[tickboo] 16/8/2021 08:32

Fully funded with £48m in bank Dec 31st until 2023 and assuming LFT sales of 5m/month from next month we'll be generating cash.

[jimarilo] 16/8/2021 08:23

I can't wait for home use the lft on fruit juice, water, coke or what ever you like

It will confirm all the false positives tested on any substance lol

All pcr and lft's are FAKE FAKE FAKE !!!

I don't ever see these tests being offered to people at home, as it will expose the scam !!

[bloomberg2] 16/8/2021 08:22

Are they planning a funding round ?

[tickboo] 16/8/2021 08:03

Yeah I was at Spurs yesterday and was busy to say the least. Many on trains not wearing masks. Next batch should come off production line soon and should be a larger number and I assume will sell out. Hopefully an RNS soon too.

[amanitaangelicus] 16/8/2021 08:00

We.ve got the fall out from the footy full capacity grounds to cope with yet. The vacc might be 'on it' ...hopefully it is. Laters defo...

[amanitaangelicus] 16/8/2021 07:54

Tick ... I think that too. I was really hinting at our affimer tech being able to maybe avoid these variant issues. AS has gone out of his way to say Affid detects the Delta variant a few times now. I suspect that in the LFT industry they.ll be talk about variant change and sens/spec/accur all of the time! It.s good to hear from other testing agencies though. Just read somewhere that a high up ex DHSC guy has been working for Innova pre covid ...I.d missed that. Typical. Gotta watch the main mkts too again. Pre UKX footsie highs are around 7700 ish not that far off again now. Inflation is rather frisky - BOE seems to think it.s just a temporary, covid demand led 'catch up' - we.ll have to see - then inflation should taper off. If it doesnt or politics gets in the way of early interest rate rises we could have some hassle. The Feds actions are critical over the pond. Weakness here again today. Way, way, way busier on the roads etc down in Cambs/Oxford than ever I imagined - dire traffic jams everywhere. House prices are off the map! Oh well ... GL.

[david gruen] 16/8/2021 07:53

90-100p. Nearly in the buy zone. Just in time for winter.

[tickboo] 16/8/2021 07:36

Safe to assume Avacta's LFT wasn't part of the study so it backs up our RNS re us picking up the delta variant and 2 'leading' LFTs were poor in comparison. We need a larger study and I hope Medusa is working hard on home-use. We have the best LFT due to the Affimer but we need to commercialise better. That said we sold our first batch and I bet we will sell all we can produce and manufacturing is ramping up.

[amanitaangelicus] 16/8/2021 07:25

Courtesy of McCrudden on Nova board.Interesting read, https://www.synlab.com/human/news/news-article/german-covag-study-111The COVID-19 Antigen Study (COVAG Study), conducted by SYNLAB, the Universities of Heidelberg and Graz, and a large COVID-19 test centre in Stuttgart, is one of the most comprehensive systematic evaluations of rapid antigen testing in a real-life settingThe COVAG Study confirms a significantly lower accuracy of rapid antigen tests compared to PCR tests, determining the actual sensitivity of rapid antigen tests at about 60 percentStudy results imply that rapid antigen tests have a lower sensitivity when testing for new virus variantsEffectiveness of rapid antigen tests as a tool to control the pandemic is limited SYNLAB, Europe's leading medical diagnostic services provider, collaborated with researchers from the Universities of Heidelberg and Graz, and a large COVID-19 test centre in Stuttgart to conduct the COVID-19 Antigen Study (COVAG Study). The COVAG Study is one of the most comprehensive field research studies to systemically assess the actual sensitivity and specificity of rapid antigen tests.The results indicate that the actual sensitivity of two commonly used rapid antigen tests considered reliable, are only at 60.4 and 56.8 percent, respectively, compared to PCR tests. In addition, for the first time the COVAG Study identified a variant-dependency of rapid antigen tests: the sensitivity of the tests is significantly lower when detecting the alpha variant compared to their sensitivity when detecting the SARS-CoV-2 wild-type.338 out of 2,215 individuals participating in the study tested positive for SARS-CoV-2 using the PCR testing method. Of these 338 positive cases, however, the two rapid antigen tests only identified 204 and 192 participants, respectively, as virus carriers. In other words, rapid antigen tests missed four out of ten individuals who tested positive for SARS-CoV-2 with PCR tests. Here, the viral load was the most decisive factor for the detection of the virus. Only individuals with a very high viral load (CT value ? 20) were reliably detected as virus carriers by rapid antigen tests. The virus, however, already spreads at a medium to low viral load.In addition, the COVAG Study was the first to investigate variant dependence of rapid antigen tests in samples with moderate to high viral loads (CT value ? 30). For the SARS-CoV-2 wild-type, the two rapid antigen tests' sensitivity was determined with 87.7 and 84.0 percent, respectively. Yet, for the alpha variant the same tests' sensitivity was only at 77.1 and 72.3 percent, respectively. Compared to other circulating variants, however, the alpha variant has the lowest structural deviation from the SARS-CoV-2 wild-type. Accordingly, it can be assumed that the sensitivity of rapid antigen tests is also significantly lower for other virus variants than for the original wild-type. Meanwhile, however, the latter has been completely displaced by the spread of new variants.Univ.-Prof. Dr. Winfried März, co-author of the COVAG Study and project lead at SYNLAB, emphasises: "The COVAG Study provides valuable scientific findings regarding the properties of rapid antigen tests. Only with targeted and reliable testing, we can detect infections at an early stage and interrupt chains of infections early on. Given the potentially decreasing sensitivity of rapid antigen tests with virus variants, it is crucial to carefully consider in which cases the speed of rapid antigen tests remains preferable to the significantly higher accuracy of PCR tests. We need to minimise the risk of false certainty from false test results."The COVAG Study was conducted from February 1st to March 31st, 2021, at the Cannstatter Wasen Test Center in Stuttgart, Germany.The full COVAG Study can be read here.

[amanitaangelicus] 16/8/2021 07:21

See of red today - enjoy your day.

[muppetsportf0liodestroyed] 15/8/2021 22:20

Ovenman after losing 95% of his money and working the bins 🗑 daily thinks he has an investment portfolio. The muppets portfolio was 1 share which went down by 95%

[muppetsportf0liodestroyed] 15/8/2021 22:18

Poor Ovenman. Lost 95% of his life saving in avact when everyone else Made money 💰 😢😢😢

[muppetsportf0liodestroyed] 15/8/2021 22:14

The Truth Hurts hey ovenman 😂 just admit it!

[mikro1] 15/8/2021 18:10

Mark 0419 - Myles McNulty has been wrong in almost every optimistic prediction he has made about Avacta, and so have you.

[muppetsportf0liodestroyed] 15/8/2021 17:10

The Latest is Taliban has seized control of Kabul x

[boysie72] 15/8/2021 16:45

Another thick grooming troll filtered in to the one brain cell bucket.

[mark0419] 15/8/2021 16:26

In the papers today..........https://www.theguardian.com/world/2021/aug/15/new-covid-variants-will-set-us-back-a-year-experts-warn-uk-government

[mark0419] 15/8/2021 16:22

Good find by energyshares over on Lse.LFTs going to be BIG in the travel industry in the next few weeks/months.Enter Avacta with their sovereign test........Myles mcnulty is very quiet over on twitter since he's had a meeting with Avacta.perhaps he's been gagged about all the big contracts awaiting signing..............EU rejects Surescreen test.AS could be right about concentrating on EU.https://ec.europa.eu/health/sites/default/files/preparedness_response/docs/covid-19_rat_common-list_addendum_en.pdf